tbuckley/cabot-search huggingface dataset:
Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study
Authors: Esther N. Dekker, Jacob L. van Dam, Quisette P. Janssen, Marc G. Besselink, Annissa DeSilva, Deesje Doppenberg, Casper H.J. van Eijck, Naaz Nasar, Eileen M. O'Reilly, Alessandro Paniccia, Laura R. Prakash, Ching-Wei D. Tzeng, Eva M.M. Verkolf, Alice C. Wei, Amer H. Zureikat, Matthew H.G. Katz, Bas Groot Koerkamp, Rudy el Asmar, Dana Haviland, Crisanta Ilagan, Caitlin McIntyre, Sarah McIntyre, Thomas F. Stoop, Rutger T. Theijse
Journal: Journal of Clinical Oncology (2024)

PURPOSE Previous studies suggest that besides anatomy (A: resectable, borderline resectable [BR], or locally advanced [LA]) also biologic (B: carbohydrate antigen 19-9 [CA 19-9]) and conditional (C: performance status) factors should be considered when staging patients with localized pancreatic ductal adenocarcinoma (PDAC). The prognostic value of the combined ABC factors has not been quantitatively validated. METHODS In this retrospective cohort study, we evaluated patients with localized PDAC treated with initial (modified) fluorouracil with leucovorin, irinotecan, and oxaliplatin ([m]FOLFIRINOX) at five high-volume pancreatic cancer centers in the United States and the Netherlands (2012-2019). Multivariable Cox proportional hazards analysis was used to investigate the impact of the ABC factors for overall survival (OS). RESULTS Overall, 1,835 patients with localized PDAC were included. Tumor stage at diagnosis was potentially resectable in 346 (18.9%), BR in 531 (28.9%), and LA in 958 (52.2%) patients. The baseline CA 19-9 was &gt;500 U/mL in 559 patients (32.5%). Performance status was ≥1 in 1,110 patients (60.7%). Independent poor prognostic factors for OS were BR disease (hazard ratio [HR], 1.26 [95% CI, 1.06 to 1.50]), LA disease (HR, 1.71 [95% CI, 1.45 to 2.02]), CA 19-9 &gt;500 U/mL (HR, 1.36 [95% CI, 1.21 to 1.52]), and WHO performance status ≥1 (HR, 1.31 [95% CI, 1.16 to 1.47]). Patients were assigned 1 point for each poor ABC factor and 2 points for LA disease. The median OS for patients with score 0-4 was 49.7, 29.9, 22.0, 19.1, and 14.9 months with corresponding 5-year OS rates of 47.0%, 28.9%, 19.2%, 9.3%, and 4.8%, respectively. CONCLUSION The ABC factors of tumor anatomy, CA 19-9, and performance status at diagnosis were independent prognostic factors for OS in patients with localized PDAC treated with initial (m)FOLFIRINOX. Staging of patients with localized PDAC at diagnosis should be based on anatomy, CA 19-9, and performance status.
In hypertension, with or without orthostatic hypotension, more- vs. less-intensive BP therapy improves clinical outcomes
Authors: KoKo Aung, Thwe Htay
Journal: Annals of Internal Medicine (2024)

Source CitationJuraschek SP, Hu JR, Cluett JL, et al. Orthostatic hypotension, hypertension treatment, and cardiovascular disease: an individual participant meta-analysis. JAMA. 2023;330:1459-1471. https://pubmed.ncbi.nlm.nih.gov/37847274/
Accelerated Lung Function Decline and Mucus–Microbe Evolution in Chronic Obstructive Pulmonary Disease
Authors: Oliver W. Meldrum, Gavin C. Donaldson, Jayanth Kumar Narayana, Fransiskus Xaverius Ivan, Tavleen K. Jaggi, Micheál Mac Aogáin, Lydia J Finney, James P. Allinson, Jadwiga A. Wedzicha, Sanjay H Chotirmall
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Progressive lung function loss is recognized in chronic obstructive pulmonary disease (COPD); however, no study concurrently evaluates how accelerated lung function decline relates to mucus properties and the microbiome in COPD.
Reducing Care Overuse in Older Patients Using Professional Norms and Accountability
Authors: Stephen D. Persell, Lucia C. Petito, Ji Young Lee, Daniella Meeker, Jason N. Doctor, Noah J. Goldstein, Craig R. Fox, Theresa A. Rowe, Jeffrey A. Linder, Ryan Chmiel, Yaw Amofa Peprah, Tiffany Brown
Journal: Annals of Internal Medicine (2024)

Effective strategies are needed to curtail overuse that may lead to harm.
In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo
Authors: Tanvi Gupta, Brooks D. Cash
Journal: Annals of Internal Medicine (2024)

Source CitationFord AC, Wright-Hughes A, Alderson SL, et al; ATLANTIS trialists. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:1773-1785. https://pubmed.ncbi.nlm.nih.gov/37858323/
Biomarker risk assessment model identified high-risk patients with cancer who benefit from thromboprophylaxis
Authors: Sander Veldhuyzen van Zanten, Bruce Ritchie
Journal: Annals of Internal Medicine (2024)

Source CitationAlexander M, Harris S, Underhill C, et al. Risk-directed ambulatory thromboprophylaxis in lung and gastrointestinal cancers: the TARGET-TP randomized clinical trial. JAMA Oncol. 2023;9:1536-1545. https://pubmed.ncbi.nlm.nih.gov/37733336/
AABB recommends restrictive RBC transfusions for hospitalized adults and children
Authors: Errol Moras, J. Dawn Abbott, Saraschandra Vallabhajosyula
Journal: Annals of Internal Medicine (2024)

Source CitationCarson JL, Stanworth SJ, Guyatt G, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023;330:1892-1902. https://pubmed.ncbi.nlm.nih.gov/37824153/
In T2DM with obesity, time-restricted eating increased weight loss and reduced HbA<sub>1c</sub> level at 6 mo
Authors: Joseph M. Pappachan
Journal: Annals of Internal Medicine (2024)

Source CitationPavlou V, Cienfuegos S, Lin S, et al. Effect of time-restricted eating on weight loss in adults with type 2 diabetes: a randomized clinical trial. JAMA Netw Open. 2023;6:e2339337. https://pubmed.ncbi.nlm.nih.gov/37889487/
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
Authors: Alexander H.R. Varey, Isabel Li, Mary-Ann El Sharouni, Julie Simon, Aikaterini Dedeilia, Sydney Ch'ng, Robyn P.M. Saw, Andrew J. Spillane, Kerwin F. Shannon, Thomas E. Pennington, Michael Rtshiladze, Jonathan R. Stretch, Omgo E. Nieweg, Alexander van Akkooi, Ryan J. Sullivan, Genevieve M. Boland, Jeffrey E. Gershenwald, Paul J. van Diest, Richard A. Scolyer, Georgina V. Long, John F. Thompson, Serigne N. Lo
Journal: Journal of Clinical Oncology (2024)

Improvements in recurrence-free survival (RFS) were demonstrated in two recent randomized trials for patients with sentinel node (SN)-negative stage IIB or IIC melanoma receiving adjuvant systemic therapy (pembrolizumab/nivolumab). However, adverse events also occurred. Accurate individualized prognostic estimates of RFS and overall survival (OS) would allow patients to more accurately weigh the risks and benefits of adjuvant therapy. Since the current American Joint Committee on Cancer eighth edition (AJCC-8) melanoma staging system focuses on melanoma-specific survival, we developed a multivariable risk prediction calculator that provides estimates of 5- and 10-year RFS and OS for these patients.
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership
Authors: Mohsan Subhani, Ashwin Dhanda, Adina Olaru, Louise Dunford, Nahid Ahmad, Andrew Wragg, Kate Frost, Justin Greenwood, Melinda King, Katy A Jones, William Rosenberg, Julia Sinclair, Stefan Rennick-Egglestone, Joanne R Morling, Krishna Patel, Stephen D Ryder
Journal: The Lancet. Gastroenterology & hepatology (2024)
Advancing Point-of-Care Applications with Droplet Microfluidics: From Single-Cell to Multicellular Analysis
Authors: Christina Sharkey, Rachel White, Michael Finocchiaro, Judene Thomas, Jose Estevam, Tania Konry
Journal: Annual Review of Biomedical Engineering (2024)

Recent advances in single-cell and multicellular microfluidics technology have provided powerful tools for studying cancer biology and immunology. The ability to create controlled microenvironments, perform high-throughput screenings, and monitor cellular interactions at the single-cell level has significantly advanced our understanding of tumor biology and immune responses. We discuss cutting-edge multicellular and single-cell microfluidic technologies and methodologies utilized to investigate cancer–immune cell interactions and assess the effectiveness of immunotherapies. We explore the advantages and limitations of the wide range of 3D spheroid and single-cell microfluidic models recently developed, highlighting the various approaches in device generation and applications in immunotherapy screening for potential opportunities for point-of-care approaches.
3D Traction Force Microscopy in Biological Gels: From Single Cells to Multicellular Spheroids
Authors: Brian C.H. Cheung, Rana J. Abbed, Mingming Wu, Susan E. Leggett
Journal: Annual Review of Biomedical Engineering (2024)

Cell traction force plays a critical role in directing cellular functions, such as proliferation, migration, and differentiation. Current understanding of cell traction force is largely derived from 2D measurements where cells are plated on 2D substrates. However, 2D measurements do not recapitulate a vital aspect of living systems; that is, cells actively remodel their surrounding extracellular matrix (ECM), and the remodeled ECM, in return, can have a profound impact on cell phenotype and traction force generation. This reciprocal adaptivity of living systems is encoded in the material properties of biological gels. In this review, we summarize recent progress in measuring cell traction force for cells embedded within 3D biological gels, with an emphasis on cell-ECM cross talk. We also provide perspectives on tools and techniques that could be adapted to measure cell traction force in complex biochemical and biophysical environments.
Measuring Absolute Coronary Flow and Microvascular Resistance by Thermodilution
Authors: Marta Belmonte, Emanuele Gallinoro, Nico H.J. Pijls, Dario Tino Bertolone, Danielle C.J. Keulards, Michele Mattia Viscusi, Tatyana Storozhenko, Takuya Mizukami, Thabo Mahendiran, Ruiko Seki, Stephane Fournier, Annemiek de Vos, Julien Adjedj, Emanuele Barbato, Jeroen Sonck, Peter Damman, Thomas Keeble, Samer Fawaz, Alejandro Gutiérrez-Barrios, Valeria Paradies, Frederic Bouisset, Morton J. Kern, William F. Fearon, Carlos Collet, Bernard De Bruyne
Journal: Journal of the American College of Cardiology (2024)
Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation
Authors: In-Cheol Kim, Sang Hyun Kim, Jong-Chan Youn, Darae Kim, Seonhwa Lee, Hyungseop Kim, Jin-Jin Kim, Mi-Hyang Jung, Joseph W. Rossano, Wida S. Cherikh, Jon A. Kobashigawa, Josef Stehlik
Journal: JACC Heart Failure (2024)
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Authors: Carel W le Roux, Oren Steen, Kathryn J Lucas, Elena Startseva, Anna Unseld, Anita M Hennige
Journal: The Lancet Diabetes & Endocrinology (2024)
Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Authors: Zifeng Yang, Zhengtu Li, Yangqing Zhan, Zhengshi Lin, Zhonghao Fang, Xiaowei Xu, Lin Lin, Haijun Li, Zejun Lin, Changyuan Kang, Jingyi Liang, Shiwei Liang, Yongming Li, Shaoqiang Li, Xinyun Yang, Feng Ye, Nanshan Zhong, Ping Zhang, Xiaoguang Li, Jie Peng, Sanjing Li, Rongmeng Jiang, Xiaolin Chen, Yingyun Fu, Huiqing Zeng, Xiaoju Zhang, Wei Zhang, Shenghui Yu, Feng Gao, Changqing Lin, Deguang Mu, Yanfen Chai, Mei Chen, Xianyong Zheng
Journal: The Lancet Infectious Diseases (2024)
Diagnosis and management of pyruvate kinase deficiency: international expert guidelines
Authors: Hanny Al-Samkari, Nadine Shehata, Kelly Lang-Robertson, Paola Bianchi, Andreas Glenthøj, Sujit Sheth, Ellis J Neufeld, David C Rees, Satheesh Chonat, Kevin H M Kuo, Jennifer A Rothman, Wilma Barcellini, Eduard J van Beers, Dagmar Pospíšilová, Ami J Shah, Richard van Wijk, Bertil Glader, Maria Del Mar Mañú Pereira, Oliver Andres, Theodosia A Kalfa, Stefan W Eber, Patrick G Gallagher, Janet L Kwiatkowski, Frédéric Galacteros, Carl Lander, Alejandra Watson, Riyad Elbard, Dore Peereboom, Rachael F Grace
Journal: The Lancet Haematology (2024)
Intervention Optimization: A Paradigm Shift and Its Potential Implications for Clinical Psychology
Authors: Linda M. Collins, Inbal Nahum-Shani, Kate Guastaferro, Jillian C. Strayhorn, David J. Vanness, Susan A. Murphy
Journal: Annual Review of Clinical Psychology (2024)

To build a coherent knowledge base about what psychological intervention strategies work, develop interventions that have positive societal impact, and maintain and increase this impact over time, it is necessary to replace the classical treatment package research paradigm. The multiphase optimization strategy (MOST) is an alternative paradigm that integrates ideas from behavioral science, engineering, implementation science, economics, and decision science. MOST enables optimization of interventions to strategically balance effectiveness, affordability, scalability, and efficiency. In this review we provide an overview of MOST, discuss several experimental designs that can be used in intervention optimization, consider how the investigator can use experimental results to select components for inclusion in the optimized intervention, discuss the application of MOST in implementation science, and list future issues in this rapidly evolving field. We highlight the feasibility of adopting this new research paradigm as well as its potential to hasten the progress of psychological intervention science.
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
Authors: Yiming Mu, Xiaolei Bao, Freddy G Eliaschewitz, Morten Rix Hansen, Bom Taeck Kim, Anna Koroleva, Ronald C W Ma, Tao Yang, Ning Zu, Ming Liu
Journal: The Lancet Diabetes & Endocrinology (2024)
Life Is About Change: A Professional Memoir
Authors: Marvin R. Goldfried
Journal: Annual Review of Clinical Psychology (2024)

Receiving my doctorate in 1961 just as John F. Kennedy was inaugurated president of the United States, I was inspired by his sentiment that any person can make a difference, and every person should try. In this memoir I review my professional journey of trying to make a difference in researching, teaching, supervising, and practicing clinical psychology and psychotherapy. I began my career by working on an evidence base for projective techniques. Upon joining the Stony Brook faculty, I shifted my efforts to research on and practice of behavior therapy, and then to the incorporation of cognition in developing cognitive behavioral therapy. Further work on integration consisted of closing the gap between research and practice, lowering the barriers that existed across schools of therapy, and incorporating lesbian, gay, bisexual, and transgender issues into mainstream psychology.
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease
Authors: Daniel J. McClintick, Michelle L. O’Donoghue, Gaetano M. De Ferrari, Jorge Ferreira, Xinhui Ran, KyungAh Im, J. Antonio G. López, Mary Elliott-Davey, Bei Wang, Maria Laura Monsalvo, Dan Atar, Anthony Keech, Robert P. Giugliano, Marc S. Sabatine
Journal: Journal of the American College of Cardiology (2024)
Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction
Authors: JoAnn Lindenfeld, Maria Rosa Costanzo, Michael R. Zile, Anique Ducharme, Richard Troughton, Alan Maisel, Mandeep R. Mehra, Sara Paul, Samuel F. Sears, Frank Smart, Nessa Johnson, John Henderson, Philip B. Adamson, Akshay S. Desai, William T. Abraham
Journal: Journal of the American College of Cardiology (2024)
Targeting ageing with rapamycin and its derivatives in humans: a systematic review
Authors: Deborah J W Lee, Ajla Hodzic Kuerec, Andrea B Maier
Journal: The Lancet Healthy Longevity (2024)

Rapamycin and its derivatives (rapalogs) are inhibitors of mTOR, a major regulator of the ageing process. We aimed to summarise the effects of rapamycin and its derivatives on the severity of ageing-related physiological changes and disease in adults. A search across five databases yielded 18 400 unique articles, resulting in 19 included studies. Rapamycin and its derivatives improved physiological parameters associated with ageing in the immune, cardiovascular, and integumentary systems of healthy individuals or individuals with ageing-related diseases. Overall, no significant effects on the endocrine, muscular, or neurological systems were found. The effects of rapamycin or its derivatives on the respiratory, digestive, renal, and reproductive systems were not assessed. No serious adverse events attributed to rapamycin and its derivatives were reported in healthy individuals; however, there were increased numbers of infections and increases in total cholesterol, LDL cholesterol, and triglycerides in individuals with ageing-related diseases. Future studies should assess the remaining unexamined systems and test the effects of long-term exposure to rapamycin and its derivatives.
Association of physical behaviours with sarcopenia in older adults: a systematic review and meta-analysis of observational studies
Authors: Juan Luis Sánchez-Sánchez, Lingxiao He, Javier S Morales, Philipe de Souto Barreto, David Jiménez-Pavón, Ana Carbonell-Baeza, Álvaro Casas-Herrero, Daniel Gallardo-Gómez, Alejandro Lucia, Borja del Pozo Cruz, Pedro L Valenzuela
Journal: The Lancet Healthy Longevity (2024)

BackgroundPhysical behaviours (ie, physical activity and sedentary behaviour) might have a role in the development of sarcopenia, although the evidence is unclear. We aimed to explore the association of total and intensity-specific levels of physical activity and sedentary behaviour with sarcopenia and its components (ie, muscle mass, muscle strength, and physical performance) in older adults.MethodsWe conducted a systematic review and meta-analysis and searched MEDLINE (via PubMed), Scopus, and Web of Science from inception to July 26, 2022, for peer-reviewed, observational studies or baseline data from randomised clinical trials conducted in older adults (ie, individual age ≥60 years or mean age ≥65 years) and published in English that reported on the association of physical activity or sedentary behaviour or both with sarcopenia (or its determinants: muscle mass or strength, and physical performance). Physical activity and sedentary behaviour were measured by any method. The main outcome was sarcopenia, which could be diagnosed by any means. Estimates were extracted and pooled using Bayesian meta-analytic models and publication bias was assessed using the Egger's test. This study is registered with PROSPERO, CRD42022315865.FindingsWe identified 15 766 records, of which 124 studies (230 174 older adults; 121 301 [52·7%] were female and 108 873 [47·3%] were male) were included in the systematic review. 86 studies were subsequently included in the meta-analysis. Higher levels of total physical activity were inversely associated with sarcopenia both cross-sectionally (21 studies, n=59 572; odds ratio 0·49, 95% credible interval 0·37–0·62) and longitudinally (four studies, n=7545; 0·51, 0·27–0·94). A protective association was also identified for moderate-to-vigorous physical activity in cross-sectional research (five studies, n=6787; 0·85, 0·71–0·99), whereas no association was identified for the remaining physical behaviours (ie, steps, light physical activity, or sedentary behaviour).InterpretationTotal and moderate-to-vigorous physical activity are inversely associated with sarcopenia. These findings might support the importance of moderate-to-vigorous, rather than light, intensity physical activity-based interventions to prevent sarcopenia.FundingNone.TranslationFor the Spanish translation of the abstract see Supplementary Materials section.
A psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: a single-masked, phase 3, superiority, randomised controlled trial
Authors: Claudia Cooper, Victoria Vickerstaff, Julie Barber, Rosemary Phillips, Margaret Ogden, Kate Walters, Iain Lang, Penny Rapaport, Vasiliki Orgeta, Kenneth Rockwood, Sara Banks, Marina Palomo, Laurie T Butler, Kathyrn Lord, Gill Livingston, Sube Banerjee, Jill Manthorpe, Briony Dow, Juanita Hoe, Rachael Hunter, Quincy Samus, Jessica Budgett
Journal: The Lancet Healthy Longevity (2024)

Although national guidelines recommend that everyone with dementia receives personalised post-diagnostic support, few do. Unlike previous interventions that improved personalised outcomes in people with dementia, the NIDUS-Family intervention is fully manualised and deliverable by trained and supervised, non-clinical facilitators. We aimed to investigate the effectiveness of home-based goal setting plus NIDUS-Family in supporting the attainment of personalised goals set by people with dementia and their carers.